UniQure cashes out $10M upfront to get candidate for inherited ALS
Gene therapy player uniQure has signed a new agreement with Apic Bio for its ALS gene therapy.
The biotech said Tuesday morning that it now has a global licensing deal with Apic for APB-102, a gene therapy candidate for a rare form of the disease called superoxide dismutase 1 amyotrophic lateral sclerosis, or SOD1 ALS.
SOD1 ALS is the same disease subset Biogen’s drug tofersen is attempting to treat. Biogen submitted tofersen for accelerated approval last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.